Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|RSPO3 over exp||cancer||not applicable||N/A||Preclinical - Pdx & cell culture||Emerging||In a preclinical study, advanced solid tumor cells overexpressing Rspo3 in culture and in patient-derived xenograft models demonstrated inhibition of beta-catenin activity and suppression of tumor growth when treated with RSPO3 specific antibodies, suggesting RSPO3 may be a promising therapeutic target (PMID: 26719531).||26719531|